AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26704894 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N = 382) training 3 days/week (50-55 min/session) from gestational weeks 9-11 until weeks 38-39.
Number of subjects: 765
Study 24714776 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin, Paclitaxel, and Sorafenib (CPS)
Number of subjects: 179
Study 24714776 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Paclitaxel (CP)
Number of subjects: 179
Study 22040525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soybean milk (FSM)
Number of subjects: 10
Study 22040525 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fermented soybean milk (NFSM)
Number of subjects: 10
Study 19888035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg)
Number of subjects: 143
Study 19888035 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol gel (1 mg)
Number of subjects: 143
Study 19888035 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol with daily medroxyprogesterone acetate
Number of subjects: 143
Study 19888035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 17590369 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 injection of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42
Study 17590369 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 injections of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42
Study 17590369 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of 1ml Sodium Hyaluronidate (Sinovial)
Number of subjects: 42
Study 15632778 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported upper limb endurance training
Number of subjects: 38
Study 15632778 — intervention group
Group type: COMPARATOR
Intervention: Lower limb training alone (control group)
Number of subjects: 38
Study 11720682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node surgery without axillary dissection
Number of subjects: 0
Study 11720682 — intervention group
Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 0
Study 9177594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycle (low movement)
Number of subjects: 106
Study 9177594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (medium movement)
Number of subjects: 106
Study 9177594 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic movement (high movement)
Number of subjects: 106
Study 7584261 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous recollections of intentions
Number of subjects: 0
Study 7584261 — intervention group
Group type: COMPARATOR
Intervention: Randomly sampled occasions
Number of subjects: 0
Study 3318539 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐fluoromethyl histidine, 100 mg twice daily for 3 weeks
Number of subjects: 13
Study 3318539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3318539 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐fluoromethyl histidine
Number of subjects: 13
Study 28925009 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal-preferred exercise modalities (PPEMs)
Number of subjects: 94
Study 28925009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra exercise)
Number of subjects: 94
Study 26831168 — intervention group
Group type: EXPERIMENTAL
Intervention: 62.7 ± 3.1 g of IgG IV in 2.6 ± 0.3 L of plasma within 6 h after birth
Number of subjects: 28
Study 26831168 — intervention group
Group type: COMPARATOR
Intervention: 4 L of high quality colostrum within 12 h of birth
Number of subjects: 28
Study 25651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (5 mL 1 % Naropin(®))
Number of subjects: 87
Study 25651956 — intervention group
Group type: COMPARATOR
Intervention: Saline (5 mL)
Number of subjects: 87
Study 23095606 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefaction (LG)
Number of subjects: 95
Study 23095606 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional IP (TG)
Number of subjects: 95
Study 21910713 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ at weeks 0, 2, 6, 14 and 22
Number of subjects: 868
Study 21910713 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 15 mg weekly (increased to 20 mg weekly at week 6 if PASI response < 25%)
Number of subjects: 868
Study 21910713 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (after switching from MTX at week 16)
Number of subjects: 868
Study 21910713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events (AEs)
Number of subjects: 868
Study 18165000 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 69
Study 18165000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (clodronate or pamidronate)
Number of subjects: 0
Study 12548587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates
Number of subjects: 0
Study 12548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 9754791 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (200 mg)
Number of subjects: 0
Study 9754791 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (100 mg)
Number of subjects: 0
Study 9754791 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (50 mg)
Number of subjects: 0
Study 9754791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8549083 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Number of subjects: 109
Study 8549083 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in a double-blind placebo-controlled trial on 36 elderly subjects
Number of subjects: 109
Study 2794708 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutrophic electrotherapy
Number of subjects: 0
Study 2794708 — intervention group
Group type: COMPARATOR
Intervention: Uniform 10 Hz electrotherapy
Number of subjects: 0
Study 830945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight video version of the patient interview
Number of subjects: 0
Study 830945 — intervention group
Group type: COMPARATOR
Intervention: Normal weight video version of the patient interview
Number of subjects: 0
Study 830945 — intervention group
Group type: COMPARATOR
Intervention: Audio version of the patient interview (both normal and overweight)
Number of subjects: 0
Study 30635936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromyelitis optica patients
Number of subjects: 116
Study 30635936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulfillment of at least 2 of 5 criteria
Number of subjects: 116
Study 30635936 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings and criteria performance
Number of subjects: 116
Study 28368437 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183 at 7.0 mg flat dose every 3 weeks (q3wk)
Number of subjects: 81
Study 28368437 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183
Number of subjects: 81
Study 28368437 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (days 1-5 q3wk or weekly q4wk)
Number of subjects: 81
Study 25933919 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy A
Number of subjects: 0
Study 25933919 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy B
Number of subjects: 0
Study 25933919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23966309 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (fixed-dose)
Number of subjects: 4576
Study 23966309 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation (dose-adjusted vitamin K antagonists)
Number of subjects: 4576
Study 23966309 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc score 1-2
Number of subjects: 4576
Study 23966309 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc or CHADS2 scores
Number of subjects: 4576
Study 21417594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP) plus myo-inositol (MI) 4 g/die for 12 months
Number of subjects: 155
Study 21417594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP) plus myo-inositol (MI)
Number of subjects: 155
Study 21417594 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive pill (OCP) alone
Number of subjects: 155
Study 18802361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule of specific immunotherapy (6-week duration)
Number of subjects: 96
Study 18802361 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule of specific immunotherapy (14-week duration)
Number of subjects: 96
Study 17490567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 2
Study 17490567 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2
Study 15250225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchofiberscopic (BF) injection of 4% lidocaine
Number of subjects: 26
Study 15250225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine sprayed from a 1.06 mm catheter through the BF channel
Number of subjects: 26
Study 11526793 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 75
Study 11526793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation facilities (for Schizophrenia)
Number of subjects: 75
Study 11526793 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotic disorders
Number of subjects: 75
Study 11526793 — intervention group
Group type: COMPARATOR
Intervention: Inpatient services and drugs administration
Number of subjects: 75
Study 9771513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM)
Number of subjects: 40
Study 7835013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 0
Study 7835013 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet (Control)
Number of subjects: 0
Study 3341209 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 19
Study 3341209 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing (crossover subgroup)
Number of subjects: 19
Study 3341209 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 19
Study 29857009 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid meal
Number of subjects: 23
Study 29857009 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid, LPS, or TNF‐α
Number of subjects: 23
Study 29857009 — intervention group
Group type: COMPARATOR
Intervention: Obese asthmatic patients
Number of subjects: 23
Study 28342741 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen cream
Number of subjects: 20
Study 28342741 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 26672587 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical tunnel-based low-site PD catheter implantation (n = 48)
Number of subjects: 89
Study 26672587 — intervention group
Group type: COMPARATOR
Intervention: Traditional catheter implantation by open surgery (n = 41)
Number of subjects: 89
Study 23663021 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-based intervention on clinical supervision, consisting of three sessions.
Number of subjects: 0
Study 23663021 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational preparation for supervision and systematic reflection on supervision.
Number of subjects: 0
Study 22287431 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril once daily)
Number of subjects: 506
Study 22287431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 sprays/nostril once daily)
Number of subjects: 506
Study 19297072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative treatment with triptorelin depot (GnRH-a)
Number of subjects: 33
Study 19297072 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 33
Study 17846552 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring (TM)
Number of subjects: 0
Study 17846552 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 0
Study 15474813 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 50
Study 15474813 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50
Study 15474813 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study 11723431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac mouthwash (0.074%)
Number of subjects: 50
Study 11723431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9669750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 antifactor Xa units subcutaneously once daily for 35 days)
Number of subjects: 281
Study 9669750 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 28 days after 7 days of dalteparin
Number of subjects: 281
Study 9669750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 281
Study 9669750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 9669750 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin and Placebo
Number of subjects: 281
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease < 2 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease 2 to 2.9 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease 3 to 3.9 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease 4 to 5.9 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease 6 to 7.9 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease 8 to 9.9 cm
Number of subjects: 294
Study 8166218 — intervention group
Group type: EXPERIMENTAL
Intervention: > or = 10 cm residual disease
Number of subjects: 294
Study 8166218 — intervention group
Group type: COMPARATOR
Intervention: > or = 2 cm residual disease
Number of subjects: 294
Study 3349555 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 (Group V)
Number of subjects: 77
Study 3349555 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.25 mg.kg‐1 and 0.3 mg.kg‐1
Number of subjects: 77
Study 3349555 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.05 to 0.2 mg.kg‐1
Number of subjects: 77
Study 3349555 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups IV and VI
Number of subjects: 77
Study 3349555 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 77
Study 30045292 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hand washing group (hand washing during field training starting in the first week)
Number of subjects: 1291
Study 30045292 — intervention group
Group type: COMPARATOR
Intervention: Late hand washing group (no hand washing for the first 2 weeks, began in the third week)
Number of subjects: 1291
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: csDMARD plus glucocorticoid therapy (methotrexate + sulphasalazine + hydroxychloroquine + i.a. glucocorticoids or methotrexate + prednisolone p.o.)
Number of subjects: 800
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate + certolizumab-pegol
Number of subjects: 800
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate + abatacept
Number of subjects: 800
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate + tocilizumab
Number of subjects: 800
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate tapering
Number of subjects: 800
Study 28376912 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed tapering (after 24 weeks)
Number of subjects: 800
Study 25750586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 25750586 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study 23017620 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved family vignette
Number of subjects: 364
Study 23017620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreligious objections vignette
Number of subjects: 364
Study 23017620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of being sued
Number of subjects: 364
Study 23017620 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal distress and perception of futile care
Number of subjects: 364
Study 20885197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program (ES): 240 ± 121 minutes of running plus 2 strength training sessions per week (120 minutes)
Number of subjects: 22
Study 20885197 — intervention group
Group type: COMPARATOR
Intervention: Endurance running (E): 276 ± 108 minutes running per week
Number of subjects: 22
Study 18769979 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM teaching
Number of subjects: 50
Study 18769979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EBM teaching)
Number of subjects: 50
Study 18769979 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM group
Number of subjects: 50
Study 18769979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 18769979 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 16792454 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (SMT) 250 mg/h
Number of subjects: 62
Study 16792454 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMT) 500 mg/h
Number of subjects: 62
Study 14557107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methodology incorporating prior beliefs about selection bias parameters
Number of subjects: 0
Study 14557107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis for treatment comparisons
Number of subjects: 0
Study 10692276 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Number of subjects: 99
Study 9181154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 micrograms/kg)
Number of subjects: 20
Study 9181154 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (30 micrograms/kg) with PCA
Number of subjects: 20
Study 1287560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (150 kcal/kg/d with 15% of calories as protein)
Number of subjects: 22
Study 1287560 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet (6% of calories as protein)
Number of subjects: 22
Study 3981479 — intervention group
Group type: EXPERIMENTAL
Intervention: High demand task
Number of subjects: 45
Study 3981479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low demand task
Number of subjects: 45
Study 3981479 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline sessions)
Number of subjects: 45
Study 31903654 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB-based programme (n = 15)
Number of subjects: 35
Study 31903654 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 35
Study 29466911 — intervention group
Group type: EXPERIMENTAL
Intervention: Study 1 (Time2bHealthy)
Number of subjects: 119
Study 29466911 — intervention group
Group type: COMPARATOR
Intervention: Study2Diet
Number of subjects: 119
Study 29466911 — intervention group
Group type: COMPARATOR
Intervention: Study2PA
Number of subjects: 119
Study 29466911 — intervention group
Group type: COMPARATOR
Intervention: Study2Combo
Number of subjects: 119
Study 26607637 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 970
Study 26607637 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 970
Study 25636291 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinjingjie mouthrinse (5 mL, 4 times daily during radiotherapy)
Number of subjects: 60
Study 25636291 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 22373953 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (400mg) daily
Number of subjects: 647
Study 22373953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground fish (529±109mg) daily
Number of subjects: 647
Study 22373953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation, received vitamin A as placebo)
Number of subjects: 647
Study 22373953 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (both forms)
Number of subjects: 647
Study 20202290 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in saturated fat
Number of subjects: 486
Study 20202290 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet rich in monounsaturated fat
Number of subjects: 486
Study 20202290 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet with very long-chain n-3 PUFA supplementation
Number of subjects: 486
Study 20202290 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet without very long-chain n-3 PUFA supplementation
Number of subjects: 486
Study 18978320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 273
Study 15742593 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Number of subjects: 22
Study 15742593 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intra-articular injection of bupivacaine, morphine, and epinephrine
Number of subjects: 22
Study 14569937 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 33
Study 14569937 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP chemotherapy
Number of subjects: 33
Study 10873691 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-view mammography
Number of subjects: 110
Study 10873691 — intervention group
Group type: COMPARATOR
Intervention: One-view mammography
Number of subjects: 110